Serum Squamous Cell Carcinoma Antigen Level and Tumor Volume in Head and Neck Cancer

Overview

Correlation between serum squamous cell carcinoma antigen level and tumor volume in Head and Neck Cancer is to determine a correlation between level of serum squamous cell carcinoma antigen and tumor volume in Head and Neck Caner measured by cross-sectional imaging.

Full Title of Study: “Correlation Between Serum Squamous Cell Carcinoma Antigen Level and Tumor Volume in Head and Neck Cancer”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Cross-Sectional
  • Study Primary Completion Date: August 2018

Detailed Description

The study is a cross-sectional study. A single measurement of serum squamous cell carcinoma antigen level is performed in the eligible Head and Neck squamous cell carcinoma patients. The study tool measuring serum squamous cell carcinoma antigen level is ARCHITECT SCC (Abbott). The gross tumor volume in the cross sectional imaging obtained within 2 weeks of each patient is calculated with the typical ellipsoid formula. Correlation between both parameters will be determined.

Interventions

  • Other: Non-interventional study

Arms, Groups and Cohorts

  • Head and Neck squamous cell carcinoma
    • A single measurement of serum squamous cell carcinoma antigen level is performed in the eligible Head and Neck squamous cell carcinoma patients. The study tool measuring serum squamous cell carcinoma antigen level is ARCHITECT SCC (Abbott). The gross tumor volume in the cross sectional imaging obtained within 2 weeks of each patient is calculated with the typical ellipsoid formula.

Clinical Trial Outcome Measures

Primary Measures

  • Correlation between serum squamous cell carcinoma antigen and tumor volume
    • Time Frame: 2 weeks

Participating in This Clinical Trial

Inclusion Criteria

  • Histologically proven squamous cell carcinoma in Head and Neck – Getting a cross-sectional imaging of Head and Neck within 2 weeks of collecting serum squamous cell carcinoma antigen Exclusion Criteria:

  • Metastatic disease – Accompanied Non-Head and Neck squamous cell carcinoma – Nasopharyngeal, thyroid, salivary, nose and paranasal sinus carcinoma – Skin disease: eczema, erythrodermic epidermitis, pemphigus, and psoriasis – Pulmonary disease: tuberculosis, adult respiratory distress syndrome, pulmonary infiltration with eosinophilia, sarcoidosis, and bronchogenic cyst – Renal failure – Using antihistamine eye drops

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Prince of Songkla University
  • Provider of Information About this Clinical Study
    • Principal Investigator: Kitti Jantharapattana, M.D., Assistant Professor – Prince of Songkla University

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.